Stockscreener 앱 받기
4.35
3.57%
0.15
전일 마감가:
$4.20
열려 있는:
$4.2
하루 거래량:
317.54K
Relative Volume:
0.86
시가총액:
$346.46M
수익:
$16.72M
순이익/손실:
$-77.80M
주가수익비율:
-4.1143
EPS:
-1.0573
순현금흐름:
$-43.78M
1주 성능:
+10.13%
1개월 성능:
-2.90%
6개월 성능:
+123.08%
1년 성능:
+369.00%
1일 변동 폭
$4.07
$4.43
1주일 범위
$3.89
$4.69
52주 변동 폭
$0.75
$5.54
Prelude Therapeutics Inc Stock (PRLD) Company Profile
명칭
Prelude Therapeutics Inc
전화
(302) 467-1280
주소
175 INNOVATION BOULEVARD, WILMINGTON
Compare PRLD vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PRLD
Prelude Therapeutics Inc
|
4.35 | 355.22M | 16.72M | -77.80M | -43.78M | -1.0573 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Prelude Therapeutics Inc Stock (PRLD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-09-19 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2024-06-20 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2024-03-13 | 개시 | JMP Securities | Mkt Outperform |
| 2024-02-20 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2023-12-19 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2022-11-21 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2022-09-09 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2022-07-29 | 개시 | Jefferies | Buy |
| 2022-03-15 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2022-02-28 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2021-10-08 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2021-07-27 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2021-04-26 | 개시 | H.C. Wainwright | Buy |
| 2021-03-09 | 개시 | Barclays | Overweight |
| 2020-11-20 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2020-10-20 | 개시 | BofA Securities | Buy |
| 2020-10-20 | 개시 | Goldman | Neutral |
| 2020-10-20 | 개시 | Morgan Stanley | Equal-Weight |
모두보기
Prelude Therapeutics Inc 주식(PRLD)의 최신 뉴스
PRLD Q1 2026 Earnings: EPS Beat Drives Strong Stock ReactionEPS Growth Rate - newsline.com
[Form 4] Prelude Therapeutics Inc Insider Trading Activity - Stock Titan
Director at Prelude Therapeutics (PRLD) awarded 38,000 stock options - Stock Titan
Prelude Therapeutics (PRLD) director receives 38,000 stock options at $3.94 strike - Stock Titan
PRLD: All director, auditor, and executive compensation proposals were approved by shareholder vote - TradingView
PRLD: All proposals passed, directors elected, auditor ratified, and no shareholder questions submitted - TradingView
PRLD Technical Analysis | Trend, Signals & Chart Patterns | PRELUDE THERAPEUTICS INC (NASDAQ:PRLD) - ChartMill
Prelude Therapeutics Rises Pre-Market With Focus on Two Cancer Drugs - Bez Kabli
Prelude Therapeutics Reports Earnings and Advances Precision Oncology Pipeline - asatunews.co.id
Prelude Therapeutics Reports First Quarter Financial Results and Pipeline Expansion - HarianBasis.co
Goldman Sachs Initiates Coverage on Prelude Therapeutics: What It Could Mean for InvestorsEPS Growth Report - newsline.com
Goldman Sachs Initiates Coverage of Prelude Therapeutics (PRLD) - Yahoo Finance
PRLD Stock Price, Quote & Chart | PRELUDE THERAPEUTICS INC (NASDAQ:PRLD) - ChartMill
Prelude Therapeutics Drops 5.5% as Biotech Sector Faces Headwinds – Key Support Levels in FocusBollinger Squeeze - The Legal Advocate
Prelude Therapeutics (PRLD) Extends Gains: Support Holds, Resistance in FocusFear Greed Index - The Legal Advocate
PRLD Q1 2026 Earnings: Narrower-Than-Expected Loss as Clinical Pipeline AdvancesOne-Time Gain Impact - newsline.com
Prelude Therapeutics Announces First Quarter 2026 Financial Results and Provides Corporate Update - geneonline.com
Prelude Therapeutics: Current Cash Runway Into 2Q 2028 >PRLD - Moomoo
New PROTACs reported in Prelude Therapeutics patent - BioWorld News
Prelude Therapeutics Incorporated (NASDAQ:PRLD) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates - Sahm
Earnings Beat: Prelude Therapeutics Incorporated (NASDAQ:PRLD) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts - Yahoo Finance
Goldman Sachs initiates Prelude Therapeutics stock coverage as Early-Stage Biotech - Investing.com India
Prelude Therapeutics (PRLD) price target increased by 11.49% to 7.01 - MSN
Prelude Therapeutics (PRLD) Losses Narrow In Q1 2026 Challenging Bearish Narratives - Sahm
TradingKey - TradingKey
Jefferies raises Prelude Therapeutics stock price target on pipeline progress By Investing.com - Investing.com Australia
Prelude (PRLD) Reports Progress on Strategic Initiatives and Cas - GuruFocus
Prelude Therapeutics Reports Q1 2026 Results, Advances Precision Oncology Pipeline and Extends Cash Runway to 2028 - Minichart
Prelude Therapeutics (NASDAQ:PRLD) Reports Narrower Quarterly Loss, Shares Rise on Cash Runway Extension - ChartMill
Prelude Therapeutics Inc 1Q 2026: Revenue $4.58M, EPS $(0.13) — 10-Q Summary - TradingView
Prelude Therapeutics Initiates Phase 1 Study of PRT12396 and Provides R&D Pipeline Update - Quiver Quantitative
Prelude Therapeutics Q1 net loss narrows as expenses fall - TradingView
Prelude Therapeutics (NASDAQ: PRLD) trims Q1 2026 loss and extends cash runway to 2028 - Stock Titan
Prelude Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update - Weekly Voice
Prelude Therapeutics Is Maintained at Buy by HC Wainwright & Co. - Moomoo
Wall Street Analysts Think Prelude Therapeutics (PRLD) Could Surge 33.59%: Read This Before Placing a Bet - Yahoo Finance
Prelude Therapeutics Inc expected to post a loss of 24 cents a shareEarnings Preview - TradingView
PRLD Initiates Coverage On Prelude Therapeutics -- Price Target Announced at $9.00 - GuruFocus
D. Boral Capital Initiates Prelude Therapeutics(PRLD.US) With Buy Rating, Announces Target Price $9 - Moomoo
Prelude Therapeutics (PRLD) price target increased by 19.35% to 6.29 - MSN
Prelude Therapeutics (PRLD) Presents Preclinical Data for KAT6A Degarader PRT13722 in Breast Cancer - Yahoo Finance
Prelude Therapeutics (NASDAQ:PRLD) Rating Increased to Hold at Zacks Research - MarketBeat
9 Best Biotech Penny Stocks to Buy in 2026 - Insider Monkey
Prelude Therapeutics (NASDAQ: PRLD) outlines 2026 proxy votes on directors, pay and auditor - Stock Titan
Short Interest in Prelude Therapeutics Incorporated (NASDAQ:PRLD) Decreases By 22.1% - MarketBeat
HC Wainwright Issues Positive Estimate for PRLD Earnings - MarketBeat
RA Capital reports 7.88M-share Prelude Therapeutics (PRLD) stake - Stock Titan
Prelude Therapeutics (PRLD) Expected to Announce Quarterly Earnings on Tuesday - MarketBeat
H.C. Wainwright raises Prelude Therapeutics price target to $8 By Investing.com - Investing.com Canada
PRLD Maintained by HC Wainwright & Co. -- Price Target Raised to $8 - GuruFocus
HC Wainwright Issues Positive Forecast for Prelude Therapeutics (NASDAQ:PRLD) Stock Price - MarketBeat
Prelude Therapeutics Inc (PRLD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Prelude Therapeutics Inc 주식 (PRLD) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC | Director |
Apr 21 '26 |
Buy |
4.44 |
2,815,315 |
12,499,999 |
11,808,945 |
2.60%
0.94%
자본화:
|
볼륨(24시간):